Product Program year 2025 Source: CMS Open Payments

Lynozyfic

Biological Hematology and Oncology

NDC 61755-054-01

Open in the dashboard

General payments

$533,720

1,976 payments

Research payments

$15,900,876

4,352 payments

Through program year 2025, $533,720 in general payments and $15,900,876 in research payments were reported against Lynozyfic (Hematology and Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2025 General $533,720 1,976
2025 Research $15,900,876 4,352

Breakdown

Who paid General payments · program year 2025
  1. Regeneron Healthcare Solutions, Inc. $360,116 1,810 payments
  2. Regeneron Pharmaceuticals, Inc. $173,603 166 payments
Top recipients General payments · program year 2025
  1. Habte Yimer Hematology & Oncology · Tyler, TX $41,221 8% · 33 payments
  2. Irene Ghobrial Medical Oncology · Boston, MA $29,209 5% · 11 payments
  3. Rafael Fonseca Hematology · Scottsdale, AZ $27,861 5% · 10 payments
  4. Hakan Kaya Medical Oncology · Spokane, WA $24,380 5% · 24 payments
  5. Moshe Levy Medical Oncology · Dallas, TX $23,152 4% · 10 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Hematology & Oncology Internal Medicine $194,454 40% · 462 practitioners
  2. Medical Oncology Internal Medicine $150,566 31% · 106 practitioners
  3. Hematology Internal Medicine $79,518 17% · 27 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $13,632 3% · 260 practitioners
  5. Internal Medicine $10,594 2% · 36 practitioners

The top 5 of 46 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $73,074 14% · 215 recipients
  2. Florida $72,181 14% · 198 recipients
  3. California $42,272 8% · 131 recipients
  4. Michigan $38,526 7% · 35 recipients
  5. Massachusetts $36,239 7% · 6 recipients

The top 5 of 44 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

1,976 general · 4,352 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record